CO6251330A2 - Tratamiento de enfermedades y transtornos utilizando celulas formadoras de colonias de autorenovacion cultivadas y expandidas in vitro - Google Patents

Tratamiento de enfermedades y transtornos utilizando celulas formadoras de colonias de autorenovacion cultivadas y expandidas in vitro

Info

Publication number
CO6251330A2
CO6251330A2 CO09142587A CO09142587A CO6251330A2 CO 6251330 A2 CO6251330 A2 CO 6251330A2 CO 09142587 A CO09142587 A CO 09142587A CO 09142587 A CO09142587 A CO 09142587A CO 6251330 A2 CO6251330 A2 CO 6251330A2
Authority
CO
Colombia
Prior art keywords
expanded
organ
administering
tissue
subject
Prior art date
Application number
CO09142587A
Other languages
English (en)
Spanish (es)
Inventor
Gene Kopen
Joseph Wagner
Vanessa Ragaglia
Baron Heimbach
Richard Gore
Original Assignee
Garnet Biotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Garnet Biotherapeutics filed Critical Garnet Biotherapeutics
Publication of CO6251330A2 publication Critical patent/CO6251330A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0669—Bone marrow stromal cells; Whole bone marrow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722—Plasma globulins, lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
CO09142587A 2007-06-15 2009-12-14 Tratamiento de enfermedades y transtornos utilizando celulas formadoras de colonias de autorenovacion cultivadas y expandidas in vitro CO6251330A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US92915107P 2007-06-15 2007-06-15
US92915207P 2007-06-15 2007-06-15
US95520407P 2007-08-10 2007-08-10
US99609307P 2007-11-01 2007-11-01

Publications (1)

Publication Number Publication Date
CO6251330A2 true CO6251330A2 (es) 2011-02-21

Family

ID=40156544

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09142587A CO6251330A2 (es) 2007-06-15 2009-12-14 Tratamiento de enfermedades y transtornos utilizando celulas formadoras de colonias de autorenovacion cultivadas y expandidas in vitro

Country Status (14)

Country Link
US (5) US8354370B2 (enExample)
EP (1) EP2171043B1 (enExample)
JP (1) JP2010529987A (enExample)
KR (1) KR20100035648A (enExample)
CN (1) CN101835891A (enExample)
AP (1) AP2010005103A0 (enExample)
AU (1) AU2008266885A1 (enExample)
CA (1) CA2690143A1 (enExample)
CO (1) CO6251330A2 (enExample)
EA (1) EA201070022A1 (enExample)
IL (1) IL202445A0 (enExample)
MX (1) MX2009013672A (enExample)
NZ (1) NZ582616A (enExample)
WO (1) WO2008156728A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9969980B2 (en) 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
US9969977B2 (en) * 2002-09-20 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
US8354370B2 (en) 2007-06-15 2013-01-15 Garnet Biotherapeutics, Inc. Administering a biological composition or compositions isolated from self-renewing colony forming somatic cell growth medium to treat diseases and disorders
WO2010117198A2 (ko) * 2009-04-06 2010-10-14 영남대학교 산학협력단 성별 특이적 혈청의 제조방법 및 이를 이용한 바이오마커
JP2013528175A (ja) * 2010-05-28 2013-07-08 ガーネット バイオセラピューティクス インコーポレイテッド インビトロで培養し、増殖させた自己複製コロニー形成細胞由来の成分を有する、生存しているおよび生存していない生理活性デバイスの組成物ならびにそれらの使用法
EP2554662A1 (en) * 2011-08-05 2013-02-06 M Maria Pia Cosma Methods of treatment of retinal degeneration diseases
KR101548124B1 (ko) * 2011-10-04 2015-08-31 (주) 메디컬그룹베스티안 피부결함의 완화 또는 치료를 위한 세포처리 및 적용 시스템
US10016458B2 (en) 2012-04-16 2018-07-10 Baystate Health, Inc. p53 silenced endothelial progenitor cells for diabetes
US20140134732A1 (en) * 2012-11-14 2014-05-15 Wisconsin Alumni Research Foundation Simplified Compositions and Methods for Generating Neural Stem Cells From Human Pluripotent Stem Cells
GB201513996D0 (en) 2015-08-07 2015-09-23 Cell Therapy Ltd Immuno-oncology mesodermal progenitor (IOMP) cell
US11253630B2 (en) 2016-04-22 2022-02-22 Vivex Biologics Group, Inc. Malleable demineralized bone composition and method of manufacture
US11253629B2 (en) 2016-04-22 2022-02-22 Vivex Biologics Group, Inc. Bone gel sheet composition and method of manufacture
US9788950B1 (en) 2016-04-22 2017-10-17 Vivex Biomedical, Inc. Cohesive bone composition
US10596298B2 (en) 2016-04-22 2020-03-24 Vivex Biologics Group, Inc. Malleable demineralized bone composition and method of manufacture
US10463767B2 (en) 2016-04-22 2019-11-05 Vivex Biologics Group, Inc. Moldable bone composition
WO2018187786A1 (en) * 2017-04-07 2018-10-11 La Jolla Institute For Allergy And Immunology Unipotent neutrophil progenitor cells, methods of preparation, and uses thereof
CN109251885A (zh) * 2018-09-26 2019-01-22 北京添易医学研究院 医美级胎盘基蜕膜干细胞内液的制备方法
CN111394306B (zh) * 2020-04-15 2023-08-01 深圳市旷逸生物科技有限公司 一种提高脐带间充质干细胞的体外扩增速率的培养方法
CN114591910B (zh) * 2022-03-28 2023-11-21 重庆市铂而斐细胞生物技术有限公司 一种利用低氧三维环境培养的间充质干细胞富集脐血造血干细胞的方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1168205B (it) 1983-07-21 1987-05-20 Wellcome Italia Derivato di monsialo ganglioside dotato di attivita' antibatterica, antifungina ed antitumorale, composizioni che lo contengono e procedimento per la loro preparazione
US4608199A (en) 1984-03-20 1986-08-26 Arnold Caplan Bone protein purification process
US4609551A (en) 1984-03-20 1986-09-02 Arnold Caplan Process of and material for stimulating growth of cartilage and bony tissue at anatomical sites
US4620327A (en) 1984-07-05 1986-11-04 Caplan Arnold I Process of adapting soluble bone protein for use in stimulating osteoinduction
US5744347A (en) * 1987-01-16 1998-04-28 Ohio University Edison Biotechnology Institute Yolk sac stem cells and their uses
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US6010696A (en) 1990-11-16 2000-01-04 Osiris Therapeutics, Inc. Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5837539A (en) 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
US5811094A (en) 1990-11-16 1998-09-22 Osiris Therapeutics, Inc. Connective tissue regeneration using human mesenchymal stem cell preparations
US5226914A (en) 1990-11-16 1993-07-13 Caplan Arnold I Method for treating connective tissue disorders
US5733542A (en) 1990-11-16 1998-03-31 Haynesworth; Stephen E. Enhancing bone marrow engraftment using MSCS
US5197985A (en) 1990-11-16 1993-03-30 Caplan Arnold I Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells
US5591625A (en) 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
US6719972B1 (en) 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
US6174333B1 (en) 1994-06-06 2001-01-16 Osiris Therapeutics, Inc. Biomatrix for soft tissue regeneration using mesenchymal stem cells
ES2206509T3 (es) 1994-06-06 2004-05-16 Case Western Reserve University Biomatriz para la regeneracion de tejidos.
US5736396A (en) 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
US5643736A (en) 1995-02-06 1997-07-01 Osiris Therapeutics, Inc. Monoclonal antibodies for human osteogenic cell surface antigens
US5716616A (en) 1995-03-28 1998-02-10 Thomas Jefferson University Isolated stromal cells for treating diseases, disorders or conditions characterized by bone defects
US6653134B2 (en) 1995-03-28 2003-11-25 Cp Hahnemann University Isolated stromal cells for use in the treatment of diseases of the central nervous system
US6974571B2 (en) 1995-03-28 2005-12-13 Thomas Jefferson University Isolated stromal cells and methods of using the same
US5728581A (en) 1995-06-07 1998-03-17 Systemix, Inc. Method of expanding hematopoietic stem cells, reagents and bioreactors for use therein
CN1209836A (zh) 1995-12-29 1999-03-03 阿尔格公司 骨髓基质细胞的扩展
US5811297A (en) * 1996-03-07 1998-09-22 Amba Biosciences, Llc Immortalized hematopoietic cell lines, cell system thereof with stromal cells, in vitro, ex vivo and in vivo uses, & in vitro generation of dendritic cells and macrophages
US6368636B1 (en) * 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
EP1096941B1 (en) 1998-05-07 2005-08-10 University Of South Florida Bone marrow cells as a source of neurons for brain and spinal cord repair
CA2348770A1 (en) 1998-10-26 2000-05-04 Philadelphia Health & Education Corporation Stromal cell use
US6184035B1 (en) 1998-11-18 2001-02-06 California Institute Of Technology Methods for isolation and activation of, and control of differentiation from, skeletal muscle stem or progenitor cells
US20030003572A1 (en) 1999-03-05 2003-01-02 David J. Anderson Isolation and enrichment of neural stem cells from uncultured tissue based on cell-surface marker expression
AU780994B2 (en) 1999-05-14 2005-04-28 Henry Ford Health System Bone marrow transplantation for treatment of stroke
US6226914B1 (en) * 1999-06-25 2001-05-08 Waymon Burton Reed Firearm safety apparatus
AUPQ147799A0 (en) 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
EP1226233B1 (en) 1999-08-05 2011-06-29 ABT Holding Company Multipotent adult stem cells and methods for isolation
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US8075881B2 (en) 1999-08-05 2011-12-13 Regents Of The University Of Minnesota Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure
AU7611500A (en) 1999-09-24 2001-04-24 Abt Holding Company Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
EP1227825A4 (en) 1999-10-29 2003-07-02 Philadelphia Health & Educatio Isolation and expansion of human marrow stromal cells
FR2801979B1 (fr) 1999-12-03 2002-02-08 Oreal Utilisation d'un anticorps specifique des fibroblastes papillaires comme marqueur de qualite d'une peau
US7544509B2 (en) 2000-01-24 2009-06-09 Mcgill University Method for preparing stem cell preparations
AU3685401A (en) 2000-02-11 2001-08-20 Philadelphia Health Differentiation of bone marrow cells into neuronal cells and uses therefor
AU2001246894A1 (en) 2000-04-11 2001-10-23 Kyowa Hakko Kogyo Co. Ltd. Alpha1,2-fucosyltransferase and process for producing fucose-containing complex carbohydrate
JP2004511266A (ja) 2000-04-12 2004-04-15 チルドレンズ　ホスピタル　オブ　フィラデルフィア 間葉間質細胞に対する治療的利用法
AU2001285359A1 (en) 2000-09-01 2002-03-13 Neuronyx, Inc. Novel synthetic gangliosides
AU2002224444A1 (en) 2000-10-24 2002-05-06 Children's Hospital Of Philadelphia Therapeutic uses for mesenchymal stromal cells
CA2438501C (en) 2001-02-14 2014-09-16 Leo T. Furcht Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
US7056738B2 (en) 2001-03-23 2006-06-06 Tulane University Early stage multipotential stem cells in colonies of bone marrow stromal cells
US20030003090A1 (en) 2001-05-31 2003-01-02 Prockop Darwin J. Directed in vitro differentiation of marrow stromal cells into neural cell progenitors
US20030059941A1 (en) 2001-06-14 2003-03-27 Prockop Darwin J. Transduced marrow stromal cells
US20030017587A1 (en) 2001-07-18 2003-01-23 Rader William C. Embryonic stem cells, clinical applications and methods for expanding in vitro
US9969980B2 (en) 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
US9969977B2 (en) 2002-09-20 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
JP2006516134A (ja) * 2002-12-24 2006-06-22 アン−ゴ−ゲン・インコーポレイテッド 封入化細胞療法
WO2004072226A2 (en) 2003-02-13 2004-08-26 Reprocell Inc. Marker for undifferentiated state of cell and composition and method for separation and preparation of stem cells
WO2006050091A2 (en) * 2004-10-28 2006-05-11 Medivas, Llc Bioactive wound dressings and implantable devices and methods of use
CA2564679C (en) * 2004-03-22 2015-06-23 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
CA2566561C (en) * 2004-06-04 2013-01-08 Universite Pierre Et Marie Curie - Paris Vi A method for producing red blood cells
JP2008501724A (ja) * 2004-06-11 2008-01-24 ヴィクトリアン ティッシュ エンジニアリング センター プロプライアトリー リミテッド 組織材料およびマトリックス
US8354370B2 (en) 2007-06-15 2013-01-15 Garnet Biotherapeutics, Inc. Administering a biological composition or compositions isolated from self-renewing colony forming somatic cell growth medium to treat diseases and disorders

Also Published As

Publication number Publication date
US20120148544A1 (en) 2012-06-14
EP2171043A1 (en) 2010-04-07
EP2171043A4 (en) 2010-08-11
US20120156192A1 (en) 2012-06-21
US20140099329A1 (en) 2014-04-10
CA2690143A1 (en) 2008-12-24
AP2010005103A0 (en) 2010-02-28
EP2171043B1 (en) 2015-03-18
WO2008156728A1 (en) 2008-12-24
AU2008266885A1 (en) 2008-12-24
KR20100035648A (ko) 2010-04-05
NZ582616A (en) 2012-07-27
CN101835891A (zh) 2010-09-15
US20140086884A1 (en) 2014-03-27
JP2010529987A (ja) 2010-09-02
US20090053183A1 (en) 2009-02-26
EA201070022A1 (ru) 2010-06-30
US8354370B2 (en) 2013-01-15
MX2009013672A (es) 2010-03-30
IL202445A0 (en) 2011-08-01

Similar Documents

Publication Publication Date Title
Debnath et al. Standardization and quality assessment for clinical grade mesenchymal stem cells from human adipose tissue
Mabuchi et al. Prospective isolation of resident adult human mesenchymal stem cell population from multiple organs
JP2008546397A5 (enExample)
Rochefort et al. Multipotential mesenchymal stem cells are mobilized into peripheral blood by hypoxia
Ishige et al. Comparison of mesenchymal stem cells derived from arterial, venous, and Wharton’s jelly explants of human umbilical cord
Sabapathy et al. Human Wharton’s jelly mesenchymal stem cells plasticity augments scar-free skin wound healing with hair growth
Rodríguez‐Lozano et al. Mesenchymal stem cells derived from dental tissues
Tomar et al. Human gingiva-derived mesenchymal stem cells are superior to bone marrow-derived mesenchymal stem cells for cell therapy in regenerative medicine
Suchánek et al. Stem cells from human exfoliated deciduous teeth-isolation, long term cultivation and phenotypical analysis
Karystinou et al. Distinct mesenchymal progenitor cell subsets in the adult human synovium
PH12019500187A1 (en) A method of isolating mesenchymal stem cells from umbilical cord amniotic membrane using a cell culture medium
SI2944688T1 (en) Use of stromal stem cells derived from fat tissues in the treatment of fistula
Kok et al. Dental pulp stem cell heterogeneity: finding superior quality “needles” in a dental pulpal “haystack” for regenerative medicine‐based applications
Tran et al. Various methods for isolation of multipotent human periodontal ligament cells for regenerative medicine: Tran et al.
Lee et al. Stem and progenitor cells in human umbilical cord blood
JP2002517227A5 (ja) 造血幹細胞を試験管内で維持する方法と組成物
CY1116198T1 (el) Ταυτοποιηση και απομονωση πολυδυναμων κυτταρων απο μη-οστεοχονδρινο μεσεγχυματικο ιστο
Fossett et al. The effects of ageing on proliferation potential, differentiation potential and cell surface characterisation of human mesenchymal stem cells
Nel et al. Determinants of dental pulp stem cell heterogeneity
Pilbauerova et al. Enzymatic Isolation, Amplification and Characterization of Dental Pulp Stem Cells.
Yamachika et al. Bone regeneration from mesenchymal stem cells (MSCs) and compact bone-derived MSCs as an animal model
Zaki et al. Comparative characterization and osteogenic/adipogenic differentiation of mesenchymal stem cells derived from male rat hair follicles and bone marrow
Tan et al. Immunomodulative effects of mesenchymal stem cells derived from human embryonic stem cells in vivo and in vitro
Ghasemzadeh-Hasankolaei et al. Male and female rat bone marrow-derived mesenchymal stem cells are different in terms of the expression of germ cell specific genes
CN101198691A (zh) 多种系干细胞的分离

Legal Events

Date Code Title Description
FA Application withdrawn